Kieburtz, Karl, McGarry, A, McDermott, M, Huntington Study Group HART Investigators,

We examined the effects of 3 dosages of pridopidine, a dopamine-stabilizing compound, on motor function and other features of Huntington’s disease, with additional evaluation of its safety and tolerability. This was a randomized, double-blind, placebo-controlled trial in outpatient neurology clinics at 27 sites in the United States and Canada. Two hundred twenty-seven subjects enrolled from […]

Kieburtz, Karl, Landwehrmeyer, G. B., HORIZON Investigators of the Huntington Study Group,, European Huntington's Disease Network,

BACKGROUND Latrepirdine is an orally administered experimental small molecule that was initially developed as an antihistamine and subsequently was shown to stabilize mitochondrial membranes and function, which might be impaired in Huntington disease. OBJECTIVE To determine the effect of latrepirdine on cognition and global function in patients with mild to moderate Huntington disease. DESIGN Randomized, […]

Farlow, Martin, Arnold, Steven E., van Dyck, Christopher H., Aisen, Paul S, Snider, B. Joy, Porsteinsson, Anton P., Friedrich, Stuart, Dean, Robert A., Gonzales, Celedon, Sethuraman, Gopalan, Demattos, Ronald B., Mohs, Richard, Paul, Steven M., Siemers, Eric R.

Objectives: To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of 12 weekly infusions of solanezumab, an anti-β-amyloid (Aβ) antibody, in patients with mild-to-moderate Alzheimer’s disease. Cognitive measures were also obtained.; Methods: In this phase 2, randomized, double-blind, placebo-controlled clinical trial, 52 patients with Alzheimer’s disease received placebo or antibody (100 mg every 4 weeks, 100 […]

Dubois, Bruno, Zaim, Mohammed, Touchon, Jacques, Vellas, Bruno, Robert, Philippe, Murphy, Michael F., Pujadas-Navinés, Francesc, Rainer, Michael, Soininen, Hilkka, Riordan, Henry J., Kanony-Truc, Claire

New criteria related to prodromal Alzheimer’s disease (AD) have been proposed to overcome the issue of heterogeneity of patients with mild cognitive impairment (MCI) and to better define patients in early stage AD. Only few therapeutic trials, if any, have been reported using this newly defined population. The objective of this study was to assess […]

Newhouse, P., Kellar, K., Aisen, P., White, H., Wesnes, K., Coderre, E., Pfaff, A., Wilkins, H., Howard, D., Levin, E. D.

Objective: To preliminarily assess the safety and efficacy of transdermal nicotine therapy on cognitive performance and clinical status in subjects with mild cognitive impairment (MCI).; Methods: Nonsmoking subjects with amnestic MCI were randomized to transdermal nicotine (15 mg per day or placebo) for 6 months. Primary outcome variables were attentional improvement assessed with Connors Continuous […]